ArticleDisease models & mechanisms2026
Characterising skull pathologies in the Sost-deficient mouse for preclinical evaluation of sclerosteosis treatments.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Facial paralysis, hearing loss and potentially lethal raised intracranial pressure are primary symptoms of sclerosteosis, an ultra-rare, autosomal recessive high bone mass (HBM) condition that predominantly manifests in skull pathologies. Non-invasive treatment remains an unmet clinical need. Recently, PORCN inhibition has been shown to reduce bone mass in young Sost-deficient (Sost-/-) mice. In this paper, we characterised sclerosteosis skull pathologies at later adult stages using a Sost-/- mouse model, with a view to drug efficacy evaluation. This revealed that male and female 9-month-old Sost-/- mice recapitulate the skull overgrowth and neural impingement of human sclerosteosis. We observed that the foramen magnum was narrowed in Sost-/- mice, and that parietal bone mass and thickness were significantly elevated. Otosclerosis was apparent, and animals exhibited significant hearing loss at age 8-9 months. Further, prominent mandibles highlighted hyperostosis in the jaw. Sexual dimorphism was also evident in the Sost-/- mice, underscoring the importance of including both sexes in HBM studies. This study provides new insight into Sost-/--skull-related pathology and further validates Sost-/- mice as a valuable model for investigating potential treatments for sclerosteosis and other HBM related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.